RxDoctor Payments Data

Melissa Best

Nurse Practitioner · Matthews, NCNPI 1073934113

Payments from drug & device makers

$809in general payments, 2019–2025

Across 33 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$246
  • Pfizer$147
  • Novo Nordisk$63
  • Exact Sciences$58
  • Abbott$44
  • Lilly USA, LLC$37
  • plus $216 from 9 others

What the payments were for

  • Food & beverage$809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$809 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,920
Medicare patients
125
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$51,049
OzempicSemaglutide21$42,883
EliquisApixaban26$31,263
FarxigaDapagliflozin Propanediol18$30,201
JardianceEmpagliflozin16$29,175
SynthroidLevothyroxine Sodium27$1,720
Gabapentin67$1,518
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,506
Fluticasone Propionate124$1,336
Albuterol Sulfate HfaAlbuterol Sulfate69$1,188
Rosuvastatin Calcium115$1,151
Pravastatin Sodium83$1,065
Atorvastatin Calcium199$1,065
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$979
Diclofenac Sodium33$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$37$51,04936 claims
Novo NordiskOzempic$63$42,88321 claims
PfizerEliquis$147$31,26326 claims
AstraZenecaFarxiga$246$30,20118 claims
Boehringer IngelheimJardiance$20$29,17516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$89487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →